Mechanisms of action of interferon-beta in multiple sclerosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 68 citations in OpenAlex.

1. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.Journal of neurology, neurosurgery, and psychiatry · 2004
   Trial
2. Relationship between Neutrophil-to-Lymphocyte Ratio and Stress in Multiple Sclerosis Patients.Journal of clinical and diagnostic research : JCDR · 2017
   Article
3. Disease-modifying therapies and infectious risks in multiple sclerosis.Nature reviews. Neurology · 2016
   Review
4. Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015
   Article
5. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.The pharmacogenomics journal · 2013
   Article
6. Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.Journal of neuroimmunology · 2012
   Article
7. The mechanism of action of interferon-β in relapsing multiple sclerosis.CNS drugs · 2011
   Review
8. Chemotherapeutics in the treatment of multiple sclerosis.Therapeutic advances in neurological disorders · 2010
   Article
9. The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.Neuroscience and behavioral physiology · 2009
   Article
10. N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats.Journal of autoimmune diseases · 2005
    Article
11. Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.Journal of neurovirology · 2002
    Review
12. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.PharmacoEconomics · 2000
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as